POSIFLEX
16.1.2023 05:26:36 CET | Business Wire | Press release
As one of the world’s top five electronic Point of Sale (POS) system suppliers, Posiflex Technology is wrapping up a particularly banner year for 2022, benefiting from vigorous refurbishments in retail and hospitality industries during the post COVID-19 pandemic era. With excellent supply chain management and risk control, Posiflex has been less affected by the global supply crisis resulted from COVID-19 lockdowns and geographical conflicts on top of other risk factors during 2022, and the company is eyeing toward a further leap in its global-leading position.
World’s 5th Ranked POS Supplier Rises to the Challenge
According to the latest survey conducted by market intelligence firm RBR, Posiflex ranks as the 5th biggest POS brand in terms of shipped units throughout 2021, with its strongest presence in Southeast Asia, the Middle East, Africa and Europe. The RBR survey also found that Posiflex rose to 1st place in countries like India, the Philippines, Saudi Arabia and Greece, with its market share in India as high as 54%, and Saudi Arabia 42%.
Why Customers Choose Posiflex: Customization Capability, Quality and Delivery
A new customer feedback analysis conducted by RBR has revealed that Posiflex customers on a worldwide base are most satisfied with the company’s professional support including customization service, reliable quality, and stable delivery (effective and efficient logistics), ranking as the top 3 Posiflex advantages in the eyes of customers.
- Customization Service and better technical support
Posiflex is the only company among the top 5 POS suppliers to adopt a vertical integration strategy— it designs, manufactures, and sells POS systems and peripherals in-house, which means it is able to provide one-stop shopping service to customers as well as small volume customization to fit specific requirements of customers from different countries with various application scenarios and needs, including OS options, logo co-branding and special peripheral specs.
As Posiflex designs and manufactures products on its own, it is well-versed in technical details of its products and can be quicker and more helpful in responding to customers’ needs.
- Reliable quality
To provide reliable products, Posiflex takes care in selecting quality materials and conducts comprehensive tests before shipment, including vibration test, drop test, plus the industry’s highest standard full-system loading test in 40°C burn-in chamber for 12+ hours for all shipping products. Customers’ feedback also shows high satisfaction with Posiflex’s product quality.
- Good command of supply chain logistics
By merging various stages of production and supply chain into its own operations, Posiflex has also achieved better command of supply chain logistics with reduced need for outside entities. This, combined with a well-managed supplier network, has accumulated into better supply resilience for Posiflex to achieve more stable product deliveries and shorter delivery times than its competitors during the global supply shortage crisis in the past two years of the pandemic.
“Your success is our vision,” said Owen Chen, CEO of Posiflex, citing the company’s core values slogan. “We combine our technological advantages with customer needs and provide the most feasible products and services for partners and end users,” said Chen.
About POSIFLEX Group
Posiflex Group is a global leading Commercial Internet of Things (CIoT) enabler dedicated to providing O2O and embedded solutions. The group now is pillared by three business entities—Posiflex Technology, Portwell Inc. and US-based KIOSK Information Systems (KIS), specialized in the manufacturing of POS, embedded IPC and self-service kiosk respectively, with a common goal in pursuing a brave new world of smart commerce, where transactions become faster and more convenient physically or digitally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
